The information on this site is provided by CodeMap®. CodeMap® remains solely responsible for its content. The information provided is for general educational purposes only and may not be conclusive or exhaustive. Recent changes in applicable law, regulations and interpretations may not be reflected in the information contained herein. For technical questions, please contact CodeMap. This website is a private website and is not associated, endorsed or authorized by the Department of Health and Human Services, the Center for Medicare and Medicaid Services or any other public or government organization or agency. Healthcare-Associated Infections Enteric Infections Women's Health & Sexually-Transmitted Infections COVID-19 Point of Care Please select your state:NATIONAL LIMIT National Limits ALABAMA ALASKA ARIZONA ARKANSAS CALIFORNIA COLORADO CONNECTICUT DELAWARE DIST of COL-DC + MD/VA Suburbs FLORIDA GEORGIA HAWAII IDAHO ILLINOIS INDIANA IOWA KANSAS KENTUCKY LOUISIANA MAINE MARYLAND MASSACHUSETTS MICHIGAN MINNESOTA MISSISSIPPI MISSOURI MONTANA NATIONAL LIMIT NEBRASKA NEVADA NEW HAMPSHIRE NEW JERSEY NEW MEXICO NEW YORK NORTH CAROLINA NORTH DAKOTA OHIO OKLAHOMA OREGON PENNSYLVANIA PUERTO RICO RHODE ISLAND SOUTH CAROLINA SOUTH DAKOTA TENNESSEE TEXAS UTAH VERMONT VIRGINIA WASHINGTON WEST VIRGINIA WISCONSIN WYOMING Fees Reflect 2025 CMS Medicare Fee Schedules Fee schedules do not reflect 2% Payment Adjustment (Sequestration). Click here for more information. Veritor The BD Veritorª Plus System is a handheld device that enables testing for Flu A+B, Group A Strep, and respiratory syncytial virus (RSV) assays. Veritor Point of Care Assays CPT® Code Description Medicare Coverage NATIONAL LIMIT Medicare Reimbursement NATIONAL LIMIT Medicaid Reimbursement Influenza   87400 Infectious agent antigen detection by immunoassay technique (eg, enzyme immunoassay [EIA], enzyme-linked immunosorbent assay [ELISA], fluorescence immunoassay [FIA], immunochemiluminometric assay [IMCA]), qualitative or semiquantitative; Influenza, A or B, each   CCI   MUE   $ 14.13 (X 2) N/A (X 2) Total Reimbursement: $28.26 $0.00 Influenza (CLIA Waived)   87400-QW Infectious agent antigen detection by immunoassay technique (eg, enzyme immunoassay [EIA], enzyme-linked immunosorbent assay [ELISA], fluorescence immunoassay [FIA], immunochemiluminometric assay [IMCA]), qualitative or semiquantitative; Influenza, A or B, each   CCI   MUE   $ 14.13 (X 2) N/A (X 2) Total Reimbursement: $28.26 $0.00 Respiratory Syncytial Virus   87420 Infectious agent antigen detection by immunoassay technique (eg, enzyme immunoassay [EIA], enzyme-linked immunosorbent assay [ELISA], fluorescence immunoassay [FIA], immunochemiluminometric assay [IMCA]), qualitative or semiquantitative; respiratory syncytial virus   CCI   MUE   $ 13.91 N/A Respiratory Syncytial Virus (CLIA Waived)   87420-QW Infectious agent antigen detection by immunoassay technique (eg, enzyme immunoassay [EIA], enzyme-linked immunosorbent assay [ELISA], fluorescence immunoassay [FIA], immunochemiluminometric assay [IMCA]), qualitative or semiquantitative; respiratory syncytial virus   CCI   MUE   $ 13.91 N/A Strep-A (CLIA Waived)   87430-QW Infectious agent antigen detection by immunoassay technique (eg, enzyme immunoassay [EIA], enzyme-linked immunosorbent assay [ELISA], fluorescence immunoassay [FIA], immunochemiluminometric assay [IMCA]), qualitative or semiquantitative; Streptococcus, group A   CCI   MUE   $ 16.81 N/A SARS-CoV-2   87426 Infectious agent antigen detection by immunoassay technique (eg, enzyme immunoassay [EIA], enzyme-linked immunosorbent assay [ELISA], fluorescence immunoassay [FIA], immunochemiluminometric assay [IMCA]), qualitative or semiquantitative; severe acute respiratory syndrome coronavirus (eg, SARS-CoV, SARS-CoV-2 [COVID-19])   CCI   MUE   $ 35.33 N/A SARS-CoV-2 (CLIA Waived)   87426-QW Infectious agent antigen detection by immunoassay technique (eg, enzyme immunoassay [EIA], enzyme-linked immunosorbent assay [ELISA], fluorescence immunoassay [FIA], immunochemiluminometric assay [IMCA]), qualitative or semiquantitative; severe acute respiratory syndrome coronavirus (eg, SARS-CoV, SARS-CoV-2 [COVID-19])   CCI   MUE   $ 35.33 N/A SARS-CoV-2 & Flu A+B   87428 Infectious agent antigen detection by immunoassay technique (eg, enzyme immunoassay [EIA], enzyme-linked immunosorbent assay [ELISA], fluorescence immunoassay [FIA], immunochemiluminometric assay [IMCA]), qualitative or semiquantitative; severe acute respiratory syndrome coronavirus (eg, SARS-CoV, SARS-CoV-2 [COVID-19]) and influenza virus types A and B   CCI   MUE   $ 70.29 N/A SARS-CoV-2 & Flu A+B (CLIA Waived)   87428-QW Infectious agent antigen detection by immunoassay technique (eg, enzyme immunoassay [EIA], enzyme-linked immunosorbent assay [ELISA], fluorescence immunoassay [FIA], immunochemiluminometric assay [IMCA]), qualitative or semiquantitative; severe acute respiratory syndrome coronavirus (eg, SARS-CoV, SARS-CoV-2 [COVID-19]) and influenza virus types A and B   CCI   MUE   $ 70.29 N/A Becton, Dickinson and Company is not responsible for any actions taken by website users in billing Medicare for Becton, Dickinson and Company products, equipment or devices, including but not limited to, any billing and/or coding errors. Website users rely on the information contained in this website at their own risk and should check with the individual Medicare contractors to verify coverage, coding and payment. The information contained in this website has been compiled by CodeMap, L.L.C. to assist Becton, Dickinson and Company customers. CodeMap, L.L.C. remains solely responsible for its content. The information provided is for general educational purposes only and may not be conclusive or exhaustive. Recent changes in applicable law, regulations and interpretations may not be reflected in the information contained herein. For technical questions, please contact CodeMap at (847) 381-5465. CodeMap® has made every reasonable effort to ensure the accuracy of the information contained on this website. However, the ultimate responsibility for correct coding and claims submission lies with the provider of services. CodeMap® makes no representation, warranty, or guarantee that this compilation of Medicare information is error-free or that the use of this information will result in Medicare coverage and subsequent payment of claims. Final coverage and payment of claims are subject to many factors exclusively controlled by CMS and its contractors. No part of this web page or data displayed may be redistributed or used without the express written consent of CodeMap®. CPT copyright 2024 American Medical Association. All rights reserved. 02/05/2025 05:50:30 18.219.201.167